144 related articles for article (PubMed ID: 37236867)
1. Unveiling the Mystery of SUMO-activating enzyme subunit 1: A Groundbreaking Biomarker in the Early Detection and Advancement of Hepatocellular Carcinoma.
Wang H; Yang T; Wu J; Chen D; Wang W
Transplant Proc; 2023 May; 55(4):945-951. PubMed ID: 37236867
[TBL] [Abstract][Full Text] [Related]
2. SUMO-Activating Enzyme Subunit 1 (SAE1) Is a Promising Diagnostic Cancer Metabolism Biomarker of Hepatocellular Carcinoma.
Ong JR; Bamodu OA; Khang NV; Lin YK; Yeh CT; Lee WH; Cherng YG
Cells; 2021 Jan; 10(1):. PubMed ID: 33477333
[TBL] [Abstract][Full Text] [Related]
3. Increased Small Ubiquitin-like Modifier-Activating Enzyme SAE1 Promotes Hepatocellular Carcinoma by Enhancing mTOR SUMOylation.
Chen Y; Peng W; Tao Q; Li S; Wu Z; Zhou Y; Xu Q; Shu Y; Xu Y; Shao M; Chen M; Shi Y
Lab Invest; 2023 Jan; 103(1):100011. PubMed ID: 36748193
[TBL] [Abstract][Full Text] [Related]
4. Novel biomarkers in hepatocellular carcinoma.
De Stefano F; Chacon E; Turcios L; Marti F; Gedaly R
Dig Liver Dis; 2018 Nov; 50(11):1115-1123. PubMed ID: 30217732
[TBL] [Abstract][Full Text] [Related]
5. Up-Regulation of SLC26A6 in Hepatocellular Carcinoma and Its Diagnostic and Prognostic Significance.
Zhu Y; Huang Y; Chen L; Guo L; Wang L; Li M; Liang Y
Crit Rev Eukaryot Gene Expr; 2021; 31(5):79-94. PubMed ID: 34591393
[TBL] [Abstract][Full Text] [Related]
6. Bioinformatics-based analysis of SUMOylation-related genes in hepatocellular carcinoma reveals a role of upregulated SAE1 in promoting cell proliferation.
Liu Y; Wang X; Zeng X; Wu Y; Liu X; Tan J; Li X
Open Med (Wars); 2022; 17(1):1183-1202. PubMed ID: 35859792
[TBL] [Abstract][Full Text] [Related]
7. Construction and Validation of a Prognostic Gene-Based Model for Overall Survival Prediction in Hepatocellular Carcinoma Using an Integrated Statistical and Bioinformatic Approach.
Dessie EY; Tu SJ; Chiang HS; Tsai JJP; Chang YS; Chang JG; Ng KL
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562824
[TBL] [Abstract][Full Text] [Related]
8. Biomarker MicroRNAs for Diagnosis, Prognosis and Treatment of Hepatocellular Carcinoma: A Functional Survey and Comparison.
Shen S; Lin Y; Yuan X; Shen L; Chen J; Chen L; Qin L; Shen B
Sci Rep; 2016 Dec; 6():38311. PubMed ID: 27917899
[TBL] [Abstract][Full Text] [Related]
9. The predictive powers of plasma trefoil factor 3 or its related micro RNAs for patients with hepatocellular carcinoma.
Zhang C; Xia R; Zhang B; Wang H
BMC Cancer; 2018 Nov; 18(1):1110. PubMed ID: 30424721
[TBL] [Abstract][Full Text] [Related]
10. Tumor-adjacent tissue co-expression profile analysis reveals pro-oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma.
Grinchuk OV; Yenamandra SP; Iyer R; Singh M; Lee HK; Lim KH; Chow PK; Kuznetsov VA
Mol Oncol; 2018 Jan; 12(1):89-113. PubMed ID: 29117471
[TBL] [Abstract][Full Text] [Related]
11. MicroRNAs as Potential Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma.
Parizadeh SM; Jafarzadeh-Esfehani R; Ghandehari M; Goldani F; Parizadeh SMR; Hassanian SM; Ghayour-Mobarhan M; Ferns GA; Avan A
Curr Drug Targets; 2019; 20(11):1129-1140. PubMed ID: 30848198
[TBL] [Abstract][Full Text] [Related]
12. Cell division cycle associated 8: A novel diagnostic and prognostic biomarker for hepatocellular carcinoma.
Cui XH; Peng QJ; Li RZ; Lyu XJ; Zhu CF; Qin XH
J Cell Mol Med; 2021 Dec; 25(24):11097-11112. PubMed ID: 34741389
[TBL] [Abstract][Full Text] [Related]
13. H2AFX might be a prognostic biomarker for hepatocellular carcinoma.
Hu H; Zhong T; Jiang S
Cancer Rep (Hoboken); 2023 Jan; 6(1):e1684. PubMed ID: 35903980
[TBL] [Abstract][Full Text] [Related]
14. The diagnostic and prognostic value of H2AFY in hepatocellular carcinoma.
Ma X; Ding Y; Zeng L
BMC Cancer; 2021 Apr; 21(1):418. PubMed ID: 33858382
[TBL] [Abstract][Full Text] [Related]
15. Uncovering the potential differentially expressed miRNAs as diagnostic biomarkers for hepatocellular carcinoma based on machine learning in The Cancer Genome Atlas database.
Zhao X; Dou J; Cao J; Wang Y; Gao Q; Zeng Q; Liu W; Liu B; Cui Z; Teng L; Zhang J; Zhao C
Oncol Rep; 2020 Jun; 43(6):1771-1784. PubMed ID: 32236623
[TBL] [Abstract][Full Text] [Related]
16. Application of microRNA and mRNA expression profiling on prognostic biomarker discovery for hepatocellular carcinoma.
Wei L; Lian B; Zhang Y; Li W; Gu J; He X; Xie L
BMC Genomics; 2014; 15 Suppl 1(Suppl 1):S13. PubMed ID: 24564407
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers for the early diagnosis of hepatocellular carcinoma.
Tsuchiya N; Sawada Y; Endo I; Saito K; Uemura Y; Nakatsura T
World J Gastroenterol; 2015 Oct; 21(37):10573-83. PubMed ID: 26457017
[TBL] [Abstract][Full Text] [Related]
18. The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma.
Trevisan França de Lima L; Broszczak D; Zhang X; Bridle K; Crawford D; Punyadeera C
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188451. PubMed ID: 33065194
[TBL] [Abstract][Full Text] [Related]
19. Multiple "Omics" data-based biomarker screening for hepatocellular carcinoma diagnosis.
Liu XN; Cui DN; Li YF; Liu YH; Liu G; Liu L
World J Gastroenterol; 2019 Aug; 25(30):4199-4212. PubMed ID: 31435173
[TBL] [Abstract][Full Text] [Related]
20. [Screening core genes and cyclin B2 as a potential diagnosis, treatment and prognostic biomarker of hepatocellular carcinoma based on bioinformatics analysis].
Yang SY; Ren H; Li CF; Tang H
Zhonghua Gan Zang Bing Za Zhi; 2020 Sep; 28(9):773-783. PubMed ID: 33053978
[No Abstract] [Full Text] [Related]
[Next] [New Search]
